- Home
- ACAD vs BOX Comparison
ACAD vs BOX Comparison
Compare ACAD & BOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- BOX
- Stock Information
- Founded
- ACAD 1993
- BOX 2005
- Country
- ACAD United States
- BOX United States
- Employees
- ACAD N/A
- BOX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- BOX Computer Software: Prepackaged Software
- Sector
- ACAD Health Care
- BOX Technology
- Exchange
- ACAD Nasdaq
- BOX Nasdaq
- Market Cap
- ACAD 4.3B
- BOX 4.6B
- IPO Year
- ACAD 2004
- BOX 2015
- Fundamental
- Price
- ACAD $21.31
- BOX $33.04
- Analyst Decision
- ACAD Buy
- BOX Buy
- Analyst Count
- ACAD 21
- BOX 10
- Target Price
- ACAD $29.25
- BOX $38.80
- AVG Volume (30 Days)
- ACAD 2.3M
- BOX 1.7M
- Earning Date
- ACAD 11-05-2025
- BOX 08-26-2025
- Dividend Yield
- ACAD N/A
- BOX N/A
- EPS Growth
- ACAD 615.00
- BOX 57.29
- EPS
- ACAD 1.33
- BOX 1.25
- Revenue
- ACAD $1,018,885,000.00
- BOX $1,125,704,000.00
- Revenue This Year
- ACAD $14.01
- BOX $8.98
- Revenue Next Year
- ACAD $11.81
- BOX $7.58
- P/E Ratio
- ACAD $16.07
- BOX $26.42
- Revenue Growth
- ACAD 14.41
- BOX 6.29
- 52 Week Low
- ACAD $13.40
- BOX $28.00
- 52 Week High
- ACAD $26.65
- BOX $38.80
- Technical
- Relative Strength Index (RSI)
- ACAD 33.94
- BOX 56.67
- Support Level
- ACAD $21.32
- BOX $31.93
- Resistance Level
- ACAD $21.96
- BOX $33.50
- Average True Range (ATR)
- ACAD 0.60
- BOX 0.59
- MACD
- ACAD -0.10
- BOX 0.05
- Stochastic Oscillator
- ACAD 30.11
- BOX 63.19
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About BOX Box Inc.
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.